Wagemans, Martijn E. H. M. http://orcid.org/0009-0007-3836-2604
Braat, Arthur J. A. T.
van Rooij, Rob
Smits, Maarten L. J.
Bruijnen, Rutger C. G.
Prince, Jip F.
Bol, Guus M.
de Jong, Hugo W. A. M.
Lam, Marnix G. E. H.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Lung Mean Dose Prediction in Transarterial Radioembolization (TARE): Superiority of [166Ho]-Scout Over [99mTc]MAA in a Prospective Cohort Study
https://doi.org/10.1007/s00270-023-03656-y
Documents that mention this clinical trial
Lung Mean Dose Prediction in Transarterial Radioembolization (TARE): Superiority of [166Ho]-Scout Over [99mTc]MAA in a Prospective Cohort Study
https://doi.org/10.1007/s00270-023-03656-y
Funding for this research was provided by:
Terumo
Article History
Received: 15 July 2023
Accepted: 27 December 2023
First Online: 7 February 2024
Declarations
:
: Marnix Lam is a consultant for Boston Scientific, Terumo/Quirem Medical, and receives research support from Boston Scientific and AAA/Novartis. Maarten Smits has served as a speaker for BTG and Terumo Medical. Arthur Braat is consultant for Boston Scientific/BTG and Terumo/Quirem Medical. All other authors declare to have no conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The Institutional Review Board granted approval for the Phase I and II Holmium Embolization Particles for Arterial Radiotherapy (HEPAR) studies, which are incorporated in this research. These studies are registered under Clinicaltrials.gov with the identifiers NCT01031784 and NCT01612325.
: Informed consent was obtained from all individual participants included in the study.
: For this type of study, consent for publication is not required.